EAI

(redirected from Epinephrine Auto-Injector)
AcronymDefinition
EAIEnterprise Application Integration
EAIElectronic Arts Intermix (New York, NY)
EAIEntreprise d'Aménagement Intérieur (French: Interior Solutions Company)
EAIÉcole d'Application de l'Infanterie (French: Infantry School Application)
EAIEngineering Animation Inc.
EAIExternal Audio in
EAIEpinephrine Auto-Injector (adrenaline dose devise)
EAIExternal Authoring Interface
EAIEpson America, Inc. (computer equipment)
EAIEast Asian Institute
EAIElephant Aid International (est. 2009)
EAIEstimated Annual Income
EAIEnterprise for ASEAN Initiative
EAIEnvironmental Associates, Inc.
EAIÉlectricité Automatisme Informatique (French: Electricity Automation Computers; Burkina Faso)
EAIEnvironmental Assessment Institute (est. 2002; Danish Ministry of the Environment)
EAIEurope Acoustique Ingénierie (French: Acoustic Engineering Europe)
EAIe-Business Application Integration
EAIEducation Associates, Inc. (South Carolina)
EAIEnvironmental Analysis, Inc. (testing firm)
EAIEasy Access, Inc. (various organizations)
EAIEurope-Afrique Intérim SA (French: Europe-Africa Interim SA; Cameroon)
EAIEmergency Action Interface
EAIEvaluación Ambiental Inicial (Guatemala)
EAIEqual Appearing Interval
EAIExternal Alarm Interface
EAIEast African Industries
EAIElectronics Associates, Incorporated
EAIExperimental Aviation Inc. (Santa Monica, California)
EAIExternal Architecture Interface
EAIEngine Air Intake
EAIElectronic Application Integrator
EAIEmployer's Agent Instruction (UK)
EAIEnterprise View A
EAIÉchange Afrique INSA (Institut National des Sciences Appliquées; French: INSA (National Institute of Applied Sciences) Africa Exchange)
References in periodicals archive ?
FDA approved the first generic epinephrine auto-injector of Teva Pharmaceuticals to treat emergency allergic reactions, including anaphylaxis.
M2 EQUITYBITES-August 12, 2019-ALK-Abello finalises US market entry strategy for new epinephrine auto-injector product
Global Banking News-August 12, 2019-ALK-Abello finalises US market entry strategy for new epinephrine auto-injector product
NORDIC BUSINESS REPORT-August 12, 2019-ALK-Abello finalises US market entry strategy for new epinephrine auto-injector product
AUVI-q 0.1 mg is the first and only epinephrine auto-injector (EAI) approved by the Food and Drug Administration for infants and toddlers weighing 16.5 to 33 pounds.
Health experts warn patients with suspected sesame allergy to be vigilant because severe symptoms could occur.  Many sesame allergic patients do not even carry epinephrine auto-injector, which could be life-saving when severe reactions occur. 
AUVI-q is the first and only epinephrine auto-injector, or EAI, approved by the FDA for infants and toddlers weighing 16.5-33 pounds.
However, price changes are on the horizon after a recent NBC News article noted the FDA has approved the first generic epinephrine auto-injector and issued new guidance for generic copies.
If there was ever a healthcare sector in desperate need of disruption, the epinephrine auto-injector market is it.
"These individuals may require an epinephrine auto-injector as part of their anaphylaxis action plan.
"While severe allergic reactions are not common, they can be life-threating and there is a need for immediate treatment with an epinephrine auto-injector (sometimes, more than one dose) followed by medical assistance at an emergency facility for observation and additional treatment.